EyePoint, Rallybio announce research collaboration

EyePoint (EYPT) and Rallybio (RLYB) announced a research collaboration. The partnership will evaluate sustained delivery of Rallybio’s inhibitor of complement component 5, or C5, using EyePoint’s proprietary Durasert technology for sustained intraocular drug delivery. The initial focus will be on geographic atrophy, an advanced form of age-related macular degeneration that leads to irreversible vision loss. Under the terms of the research collaboration, EyePoint and Rallybio will collaborate to explore and assess the viability of utilizing Rallybio’s C5 inhibitor in EyePoint’s sustained release Durasert technology, with the intention to expand the collaboration upon mutual agreement following the evaluation.